SNX8 and metabolic dysfunction-associated steatotic liver disease: SNX8 is a key inhibitor of NAFLD, which mediates FASN protein degradation through recruitment of TRIM28 and enhancement of TRIM28-FASN interactions, regulates lipid metabolism genes (FXR, ACACA, HADC 2, FXR VL 5, SCD 1), and inhibits hepatic lipid deposition.